The Department of Pharmaceuticals announced on 14 October 2026 a partnership between NIPER Raebareli and AstraZeneca India to strengthen clinical research capabilities. The collaboration aims to build a trained workforce and inspection-ready sites in 25 emerging research geographies across India, moving beyond major metropolitan areas. This initiative supports the Biopharma SHAKTI program's goal of establishing 1,000 clinical trial sites nationwide. The release does not say when the program takes effect, but it will start by adopting 25 sites for training and capability assessment.
Key points
- Partnership targets 25 emerging research geographies across India
- Supports Biopharma SHAKTI's goal of 1,000 clinical trial sites nationwide
- Focuses on training, mentoring, and site-readiness for clinical trials
- Initial phase focuses on oncology before potential expansion to other therapeutic areas
When it applies
- Signing of the MoU
Who it affects
- clinical trial sites
Refers to
- Biopharma SHAKTI